A randomized, protocol study by the Cooperative Breast Cancer Group has demonstrated the efficacy of chlorambucil, prednisone, hydrocortisone, and triiodothyronine as secondary therapy for advanced female breast cancer. Objective regression rates of 20.7% for chlorambucil and prednisone combined, 11.8% for hydrocortisone with triiodothyronine, and 9.8% for chlorambucil alone were defined. For the patient with advancing metastatic disease who has received initial hormonal therapy, it is recommended that further treatment with the combination of chlorambucil and prednisone be considered.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Mar 1973|
ASJC Scopus subject areas
- Cancer Research